Pacira Biosciences, Inc. (PCRX) Stock Price & Analysis
Pacira Biosciences, Inc. (PCRX) fell 0.19% to USD 25.88 as of July 25, 2026 at 05:19 UTC, according to Nexqual real-time market data.
PCRX last closed at USD 25.93; the session ranged USD 25.37–26.04 on volume of 377,944 shares. Market capitalization is $1.02B, with a 52-week range of USD 18.8–27.64 (NMS). Source: Nexqual, July 25, 2026 at 05:19 UTC.
Key Statistics (as of July 25, 2026 at 05:19 UTC)
| Price | USD 25.88 |
|---|---|
| Change | ▼ 0.19% (down) |
| Previous Close | USD 25.93 |
| Open | USD 25.91 |
| Day Range | USD 25.37 – 26.04 |
| 52-Week Range | USD 18.8 – 27.64 |
| Volume | 377,944 shares |
| Market Cap | $1.02B |
| Exchange | NMS |
Technical Analysis (PCRX)
Nexqual's technical model rates PCRX "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 05:19 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 64.53 (neutral) |
| vs SMA50 | Above (USD 24.05) |
| MACD | 0.49 (positive) |
Analyst Ratings (PCRX)
Wall Street analysts rate PCRX "Buy" based on 6 analysts, with a mean price target of USD 29.67 (range USD 23–38), per Nexqual as of July 25, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 29.67 |
| High Target | USD 38 |
| Low Target | USD 23 |
| Buy / Hold / Sell | 3 / 2 / 1 |
Earnings (PCRX)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD 0.65 |
| Revenue Estimate | $191.00M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.6 vs est 0.56 ▲ beat |
| 2025-12-31 | USD 0.57 vs est 0.9 ▼ miss |
| 2025-09-30 | USD 0.7 vs est 0.65 ▲ beat |
| 2025-06-30 | USD 0.74 vs est 0.71 ▲ beat |
Source: Nexqual, July 25, 2026 at 05:19 UTC.
Financials & Fundamentals (PCRX)
| Total Revenue | $734.86M |
|---|---|
| Revenue Growth (YoY) | +5.00% |
| Gross Margin | +79.33% |
| Operating Margin | +2.61% |
| Profit Margin | +0.70% |
| ROE | +0.71% |
| Debt / Equity | 62.88 |
| Current Ratio | 4.73 |
| Total Cash | $202.18M |
| Total Debt | $411.18M |
| Free Cash Flow | $98.62M |
Source: Nexqual, July 25, 2026 at 05:19 UTC.
Financial Health Score (PCRX)
Nexqual rates Pacira Biosciences, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 05:19 UTC.
| Growth | Mixed — Revenue +3.6% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 79%, operating 3% |
| Balance Sheet | Strong — $202M cash vs $411M debt |
| Cash Flow | Solid — FCF $99M, 14% margin |
| Efficiency | Weak — ROE 1%, ROA 1.3% |
Ownership (PCRX)
| Insider Ownership | +1.77% |
|---|---|
| Institutional Ownership | +115.27% |
| Shares Outstanding | 39.35M |
| Float | 33.71M |
| Short % of Float | +24.21% |
Source: Nexqual, July 25, 2026 at 05:19 UTC.
Leadership (PCRX)
Pacira Biosciences, Inc. is led by Frank D. Lee (age 57), CEO & Director, per Nexqual as of July 25, 2026 at 05:19 UTC.
| CEO & Director | Frank D. Lee (age 57) |
|---|---|
| Chief Financial Officer | Shawn M. Cross (age 57) |
Major Backers & Investors (PCRX)
Notable institutional backers of Pacira Biosciences, Inc. include Doma Perpetual Capital Management LLC, Shaw D.E. & Co., Inc., Renaissance Technologies, according to Nexqual as of July 25, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Doma Perpetual Capital Management LLC | 7.06% |
| Shaw D.E. & Co., Inc. | 5.04% |
| Renaissance Technologies | 4.64% |
| Goldman Sachs | 3.99% |
| Morgan Stanley | 3.54% |
| IMPAX FUNDS SERIES TRUST I-Impax Small Cap Fund | 1.91% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 25.93% |
| Vanguard Group | 19.02% |
| Dimensional Fund Advisors | 5.24% |
| State Street | 4.88% |
Source: Nexqual, July 25, 2026 at 05:19 UTC.
From Pacira Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
- The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve.
- It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis.
- It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUPN | Supernus Pharmaceuticals, Inc. | USD 46.2 | ▼ 1.58% |
| PTCT | PTC Therapeutics, Inc. | USD 76.82 | ▼ 2.02% |
| IRWD | Ironwood Pharmaceuticals, Inc. | USD 3.71 | ▼ 4.38% |
| COLL | Collegium Pharmaceutical, Inc. | USD 35.2 | ▲ 1.38% |
| ENTA | Enanta Pharmaceuticals, Inc. | USD 12.78 | ▼ 2.14% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:19 UTC. This page is informational and not investment advice.